An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

Sundar Jagannath, Ravi Vij, A. Keith Stewart, Suzanne Trudel, Andrzej J. Jakubowiak, Tony Reiman, George Somlo, Nizar Bahlis, Sagar Lonial, Lori A. Kunkel, Alvin Wong, Robert Z. Orlowski, David S. Siegel

Research output: Contribution to journalArticlepeer-review

104 Scopus citations

Abstract

Background: Carfilzomib is a next-generation selective proteasome inhibitor that irreversibly binds its target and has demonstrated single-agent activity in patients with bortezomib-resistant multiple myeloma (MM). PX-171-003-A0, an open-label single-arm multicenter pilot phase II study, enrolled 46 patients with relapsed MM after < 2 previous therapies including bortezomib and an immunomodulator (thalidomide or lenalidomide) and disease refractory to the last treatment regimen preceding study entry. Methods: Patients received carfilzomib 20 mg/m2 intravenously on days 1, 2, 8, 9, 15, and 16 every 28 days for up to 12 cycles. Responses in 42 evaluable patients were assessed per International Myeloma Working Group Uniform Response Criteria, with minimal response assessed per European Group for Blood and Marrow Transplantation (EBMT) criteria. Results: The primary endpoint of best ORR was 16.7%, including 7 partial responses. Median duration of response was 7.2 months. Clinical benefit response (CBR) rate was 23.8% with a median duration of response of 13.8 months. The most common treatment-emergent adverse events (AEs) of any grade were anemia (73.9%), fatigue (69.6%), and thrombocytopenia (50.0%). Notably, peripheral neuropathy and neuropathy-related AEs were generally mild and infrequent. Conclusion: This pilot study was the first phase II single-agent trial conducted with carfilzomib. Based on these findings, the study was amended to test a higher carfilzomib dose in an additional 250 patients (PX-171-003-A1).

Original languageEnglish (US)
Pages (from-to)310-318
Number of pages9
JournalClinical Lymphoma, Myeloma and Leukemia
Volume12
Issue number5
DOIs
StatePublished - Oct 2012

Keywords

  • Carfilzomib
  • Next generation
  • Proteasome inhibitor
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this